Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Eli Lilly has outpaced Ozempic-maker Novo Nordisk in the race to develop new incretin drugs.The company is set to capture 50% of the $95 billion obesity market by 2050.We got a glimpse into Eli ...